Page 35 - Technology Access Pool News Today

A proposal by India, South Africa and eight other countries call on the World Trade Organization (WTO) to exempt members from enforcing some patents, and other Intellectual Property rights under the Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS, for a limited period of time. - VnExpress International

Fair global distribution of vaccines is vital Normal text size Advertisement In March, with Italy days into its first nationwide COVID-19 lockdown, a hospital in Lombardy was running out of valves for respirators when a start-up called Isinnova came to the rescue by 3D-printing them. But this feel-good story of human ingenuity has a darker side. Isinnova had approached the valves manufacturer for access to its blueprints, only to be told those were company property subject to a patent. It meant...

Science has delivered, will the WTO deliver ? (By Brajendra Navnit) Par: Brajendra Navnit - Seneweb.com | 29 décembre, 2020 à 11:12:31  | Lu 578 Fois |  1 Commentaires Science has delivered, will the WTO deliver ? (By Brajendra Navnit) TRIPS waiver proposal from India, South Africa and other members A proposal by India, South Africa and eight other countries calls on the World Trade Organisation (WTO) to exempt member countries from enforcing some patents, and other Intellectual Propert...

Ndubuisi Francis in Abuja A group of campaigning organisations under the aegis of People’s Vaccine Alliance, have warned that nearly 70 countries may be able to vaccinate only one in 10 people against the COVID-19 pandemic as wealthier nations have bought up most of the stock. Their warning is predicated on data indicating the deals already done on the procurement of the vaccines by rich nations. According to the People’s Vaccine Alliance, rich countries with 14 per cent of the world’s po...

Can a Pharma Company Change? Profit, not altruism, motivates COVID-19 vaccine development Health Canada announced its approval of Pfizer’s COVID-19 vaccine on Dec. 9. Earlier, the news that the same vaccine was approved in the United Kingdom—and that others weren’t far behind—was a relief to many people all over the world—or at least those in developed countries that can afford the vaccine. The arrival of the vaccine also seems to have boosted public approval for the pharmaceutica...

On Friday, December 11, the Global Development Policy (GDP) Center co-hosted a webinar with the South Centre on ‘Guaranteeing Access to Medicines: Reforming Trade and Investment Treaties in the COVID-19 Era,’ featuring Carlos Correa, Executive Director of the South Centre; Mustaqeem de Gama, Counsellor at the South Africa World Trade Organization (WTO) Mission; Dr. Martin Howell Friede, Unit Lead on Vaccine Research in the Department of Immunization, Vaccines and Biologics, World Health Org...

Poor nations to miss out on vaccine as West buys most of it: Report By Bhavya Singh|   Updated: 21st December 2020 2:10 pm IST The pandemic has exposed vast inequities both within and between countries. A group of campaigning organisations have warned that nearly 70 countries may be able to vaccinate only one in ten people as wealthier nations have bought up most of the stock.  According to the People’s Vaccine alliance, rich countries with 14% of the world’s population have bought 53% o...

A people’s vaccine December 19, 2020 The latter half of November brought hope for a world facing the unprecedented public health challenge of the Covid-19 pandemic. Three pharmaceutical companies announced the results of their vaccine trials with a successful rate of over 90 percent. The UK was the first country to approve and administer the Pfizer /BioNTech vaccine. Soon after, American regulators also cleared this vaccine. Two other potential vaccines, from Moderna and Oxford in partnersh...

The arrival of the vaccine also seems to have boosted public approval for the pharmaceutical industry. Globally, the industry’s “trust and like score” grew to over 68 per cent of people surveyed in 2020 from 65 per cent in 2018. The bump in the industry’s score was probably helped by the September joint pledge from nine companies that they would “stand with science” and not try to get a vaccine approved until it had been thoroughly tested for efficacy and safety. This statement was ...

Disclosure statement In 2017-2020, Joel Lexchin received payments for being on a panel at the American Diabetes Association, for talks at the Toronto Reference Library, for writing a brief in an action for side effects of a drug for Michael F. Smith, Lawyer and a second brief on the role of promotion in generating prescriptions for Goodmans LLP and from the Canadian Institutes of Health Research for presenting at a workshop on conflict-of-interest in clinical practice guidelines. He is currentl...